Financial Advocates Investment Management Sells 6,372 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Financial Advocates Investment Management lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 42.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,739 shares of the biopharmaceutical company's stock after selling 6,372 shares during the quarter. Financial Advocates Investment Management's holdings in Gilead Sciences were worth $807,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Avior Wealth Management LLC lifted its position in Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after purchasing an additional 108 shares during the period. Southland Equity Partners LLC lifted its holdings in shares of Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after acquiring an additional 110 shares during the period. Concord Asset Management LLC VA boosted its position in shares of Gilead Sciences by 3.8% during the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock worth $256,000 after acquiring an additional 111 shares in the last quarter. Berkshire Bank increased its stake in Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 111 shares during the last quarter. Finally, TFB Advisors LLC raised its position in Gilead Sciences by 1.2% during the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock valued at $788,000 after purchasing an additional 116 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 2.0 %

NASDAQ:GILD traded down $2.00 on Friday, hitting $96.04. The stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51. The business's fifty day moving average is $93.04 and its 200 day moving average is $86.76. The company has a market cap of $119.69 billion, a PE ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business's revenue was up 7.0% on a year-over-year basis. During the same period last year, the company earned $2.29 earnings per share. On average, equities research analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Insider Activity

In other news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock worth $53,611,715 over the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on GILD. The Goldman Sachs Group lifted their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Leerink Partners raised Gilead Sciences from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price objective for the company. Finally, Morgan Stanley upgraded shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.